|
Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression Clinical research trials and Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression. Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression clinical trial. Test subjects typically obtain the finest healthcare available for their Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression  Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression
Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression
For Condition: Panic Disorder
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to examine the safety and effectiveness of the drug combination paroxetine and clonazepam in treating people with panic disorder (PD) and major depression. The main goal in treating people with PD is to rapidly reduce symptom severity and improve functioning. While numerous drug therapies have been used to treat PD, these treatments are limited by variable response rates and suboptimal side effect profiles. Evidence suggests that clonazepam given with a selective serotonin reuptake inhibitor (SSRI) can facilitate a rapid reduction in PD symptoms. However, it is unclear whether comorbid depression influences treatment response to the clonazepam and SSRI regimen. This study will examine whether combined treatment with clonazepam and the SSRI paroxetine will accelerate clinical response in participants with PD and comorbid depression. This study will also examine whether the benefits of treatment will be sustained until the end of the study despite tapering of clonazepam at the midpoint of the study. Participants in this study will be screened with medical and psychiatric interviews, a physical examination, electrocardiogram (ECG), and blood tests. Participants will then be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus placebo (an inactive pill) for 12 weeks. Participants will have weekly clinic visits during which symptoms and drug side effects will be checked and an interview to evaluate panic disorder and depression symptoms will be conducted.
Details: The main goal of treatment in patients with Panic Disorder (PD) is to effect a rapid reduction in symptom severity and improve functioning. While numerous pharmacological approaches have been used to treat PD, these treatments are limited by variable response rates, up to a 6-week lag period prior to the onset of clinical response, and sub-optimal side effect profile, including possible worsening of anxiety and insomnia. There is recent evidence that the benzodiazepine clonazepam prescribed with selective serotonin reuptake inhibitors (SSRI) can facilitate a rapid reduction of symptoms in PD. The improvement in symptoms was maintained despite tapering the clonazepam prior to the end of the study. However, it was unclear if co-morbid depression influenced the treatment response to this regimen. In addition, a recent study in patients with major depression demonstrated that combined fluoxetine-clonazepam treatment resulted in a more rapid antidepressant response than the fluoxetine-placebo combination. The proposed study will examine whether combined treatment with a clonazepam and paroxetine in patients with PD and comorbid depression will accelerate the onset of clinical response at both panic and depression symptoms. PD with comorbid major depression is a more severe disorder than PD alone. We will also examine whether the rapid and clinically meaningful benefits will be sustained until the end of the study, despite tapering off clonazepam at the midpoint of the study. If this study turns out to be the case combined SSRI-benzodiazepine treatment may become a standard initial therapeutic approach to PD and comorbid major depression.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients with a primary diagnosis of Panic Disorder without Agoraphobia or Panic Disorder with Agoraphobia according to DSM-IV criteria, and co-morbid major depressive disorder are eligible. Patients are required to have a weekly panic attack frequency of greater than or equal to 1/ week in the month prior to intake or a CGI score greater than 4 in the week prior to randomization. Patients with co-morbid major depressive disorder will be included provided that the onset of PD was earlier than the onset of the depressive disorder. The presence of co-morbid depression will be determined by using DSM-IV criteria for major depressive disorder, and HDRS scores will be in the moderately-to-severely depressed range (greater than 15). Subjects will be at least 18 years old. Those above age 65 years must be able to tolerate paroxetine starting dose of at least 20 mg daily and be without hepatic or renal impairment. Male and female subjects will be included. The patient must have given written informed consent prior to any study procedures. In addition, eligible patients must be in good physical health as confirmed by a complete physical exam (including normal vital signs), electrocardiogram, neurological exam, and routine laboratory tests of blood and urine. Patients will be drug free for at least 7 days when starting with the study medication. We will study both, untreated, symptomatic patients, and patients who did not respond to their pervious psychopharmacological treatment. The unsuccessful medication will be tapered off, and a medication-free period of 7 days will be established. EXCLUSION CRITERIA: Patients with any serious or unstable medical disorder or condition that would preclude the administration of paroxetine or clonazepam (e.g. epilepsy, severe head injury, meningitis, allergic to either drug). Patients who would be unable to comply with study procedures or assessments. Patients who meet DSM-IV lifetime criteria for benzodiazepine abuse or dependence. Patients who are on other psychotropic drugs must have discontinued them for at least 1 week prior to randomization. Patients are ineligible who experience any current signs of symptoms of drug withdrawal during taper of unsuccessful medication. Patients who are currently at high risk for homicide or suicide. Patients who had previously failed an adequate trial of paroxetine or clonazepam. Women of childbearing potential who are not practicing a clinically accepted method of contraception or who have a positive pregnancy test or who are lactating. Patients who are currently treated with fluoxetine.
Total Enrollment: 60
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020136; 02-M-0136
Study Start Date: February 27, 2002
Record last reviewed: December 18, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031317
Other Panic Disorder Studies:
1. Panic Disorder Study
2. Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients with Anxiety
3. Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia
4. Treatment of Panic Disorder: Long Term Strategies
5. Interactive Computer Treatment for Panic Disorder
Related Studies:
Other Panic Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluation of Clonazepam and Paroxetine for Panic Disorder with Depression
|
|
|
|
|
|
|
|
